Healthcare systems worldwide are facing increasing financial pressure due to rising consumption of health services, an aging population, and more patients with chronic conditions. This, combined with new technological opportunities, new diseases, and increasing expectations from patients, citizens, and healthcare professionals has led to a greater focus on resource consumption and efficiency. As a result, healthcare systems are under pressure to demonstrate value for money and optimize their use of available resources.
To determine whether investing in new medicine, medical equipment, and treatments is justified, we need to consider their benefits and costs to society. Although a new drug or technology may be safer and more effective than current options, its use in the healthcare system is not guaranteed due to various factors such as cost, implementation, and policy priorities. Therefore, it is crucial to assess the health economy before seeking approval, recommendation and/or reimbursement. With our knowledge and experience, we can help determine the value for money and budget constraints of healthcare interventions.
I. Health Economic Evaluations: We can document and demonstrate the value of medicines, treatment interventions, or technologies required by various Danish councils. We use different economic analyses, including cost-effectiveness and cost-utility analyses, to assess costs and effects at the highest quality. We also incorporate QALY, PROs, and data from clinical trials and real-world evidence (RWE) to provide comprehensive evaluations.
II. Budget-Impact Analyses: Our team also conducts budget impact analyses to assess the economic implications of implementing new interventions, such as medicines or health technologies, from the perspective of budget holders. These analyses are useful for communicating the total costs to policy-makers, decision-makers, and experts in healthcare organizations.